Lilly Expands Migraine Franchise With Reyvow Approval

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image
With approval of Reyvow, Lilly has two approved migraine therapies

Eli Lilly & Co. has its second US approval in migraine in a little over one year, as the US Food and Drug Administration okayed Reyvow (lasmiditan) for the acute treatment of migraine on 11 October.

The approval is the second part of a franchise build-out for Lilly in migraine, which saw preventive drug Emgality (galcanezumab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip